Pancreatic Cancer Research

ResearcherCold Spring Harbor LaboratoryActive in the last 2 years

Youngkyu Park

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1169-6739; OpenAlex author ID A5100724132; NIH RePORTER profile ID 10336774. Sources: OpenAlex.

Their work

Papers
24
Trials
0
Grants
1
Labs led
1
Collaborators
116
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: none · 2019: 5 papers · 2020: 2 papers · 2021: 3 papers · 2022: 3 papers · 2023: 1 paper · 2024: 3 papers · 2025: 1 paper, 1 grant · 2026: 2 papers

Papers 24

  1. Implantable Microdevices for In Vivo Assessment of Chemotherapy Response in Patient Derived Organoid Orthotopic Pancreatic Cancer Models. Co-author DOI 10.1097/sla.0000000000007071↗
  2. MYC-Mediated USP39 Upregulation Stabilizes SRSF1 in Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-25-1104↗
  3. FGFR2 Abrogation Intercepts Pancreatic Ductal Adenocarcinoma Development. Co-author DOI 10.1158/0008-5472.can-24-4576↗
  4. Engrailed-1 Promotes Pancreatic Cancer Metastasis. Co-author DOI 10.1002/advs.202308537↗
  5. A mucus production programme promotes classical pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/gutjnl-2023-329839↗
  6. Scribble Deficiency Promotes Pancreatic Ductal Adenocarcinoma Development and Metastasis. Co-author DOI 10.1158/0008-5472.can-23-3419↗
  7. Splicing Factor SRSF1 Promotes Pancreatitis and KRASG12D-Mediated Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-22-1013↗
  8. Loss of p53 tumor suppression function drives invasion and genomic instability in models of murine pancreatic cancer Co-author DOI 10.1101/2021.12.31.472823↗
  9. SPDEF promotes the classical subtype of pancreatic ductal adenocarcinoma Co-author DOI 10.1101/2022.03.18.484951↗
  10. Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer. Co-author DOI 10.1136/jitc-2021-003549↗
  11. Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer. Co-author DOI 10.1073/pnas.2016904118↗
  12. Loss of KRAS G12D feedback regulation involving splicing factor SRSF1 accelerates pancreatic cancer Co-author DOI 10.1101/2021.10.13.464210↗
  13. Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-3715↗
  14. SOAT1 promotes mevalonate pathway dependency in pancreatic cancer. Co-author DOI 10.1084/jem.20192389↗
  15. Intraductal Transplantation Models of Human Pancreatic Ductal Adenocarcinoma Reveal Progressive Transition of Molecular Subtypes. Co-author DOI 10.1158/2159-8290.cd-20-0133↗
  16. The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice. Co-author DOI 10.1126/science.aaw3145↗
  17. Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-1398↗
  18. IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/2159-8290.cd-18-0710↗
  19. Oncogenic KRAS Induces NIX-Mediated Mitophagy to Promote Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-18-1409↗
  20. Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts. Co-author DOI 10.1158/2159-8290.cd-19-0094↗
  21. Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis. Co-author DOI 10.1016/j.cell.2017.07.007↗
  22. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. Co-author DOI 10.1084/jem.20162024↗
  23. NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer. Co-author DOI 10.1016/j.cell.2016.06.056↗
  24. Organoid models of human and mouse ductal pancreatic cancer. Co-author DOI 10.1016/j.cell.2014.12.021↗

Grants 1

  1. Preclinical Models for Cancer Therapeutic Development R50CA211506↗

Closest collaborators

The 25 strongest of 116 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. David Arthur Tuveson · 24 shared papers, 2015–2026 · strength 2.98
  2. Claudia Tonelli · 6 shared papers, 2020–2025 · strength 1.02
  3. Christopher R. Vakoc · 6 shared papers, 2017–2024 · strength 0.69
  4. Tobiloba E. Oni · 8 shared papers, 2015–2021 · strength 0.61
  5. Ledong Wan · 3 shared papers, 2021–2026 · strength 0.61
  6. Adrian R. Krainer · 3 shared papers, 2021–2026 · strength 0.61
  7. Giulia Biffi · 7 shared papers, 2015–2024 · strength 0.58
  8. Hao Yuan · 7 shared papers, 2015–2022 · strength 0.55
  9. Hervé Tiriac · 8 shared papers, 2015–2024 · strength 0.55
  10. Chang‐Il Hwang · 7 shared papers, 2015–2024 · strength 0.53
  11. Brinda Alagesan · 5 shared papers, 2015–2021 · strength 0.37
  12. Daniel Öhlund · 5 shared papers, 2015–2024 · strength 0.36
  13. Ralph H. Hruban MD · 4 shared papers, 2015–2024 · strength 0.35
  14. Ela Elyada · 5 shared papers, 2015–2021 · strength 0.34
  15. Lindsey A. Baker · 5 shared papers, 2015–2020 · strength 0.32
  16. Zhikai Wang · 2 shared papers, 2021–2023 · strength 0.32
  17. Dannielle D. Engle · 5 shared papers, 2015–2019 · strength 0.29
  18. Benteng Ma · 1 shared paper, 2026 · strength 0.29
  19. Alexander J. Kral · 1 shared paper, 2026 · strength 0.29
  20. Michael Anthony Hollingsworth · 3 shared papers, 2017–2024 · strength 0.28
  21. Vincenzo Corbo · 4 shared papers, 2015–2022 · strength 0.26
  22. Kenneth H. Yu · 4 shared papers, 2015–2019 · strength 0.24
  23. Lyudmyla Demyan · 1 shared paper, 2026 · strength 0.24
  24. Matthew J. Weiss · 1 shared paper, 2026 · strength 0.24
  25. Sepideh Gholami · 1 shared paper, 2026 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.